Amlogenyx
Somerville
About Amlogenyx
Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease. It is a spin-off from Ultragenyx Pharmaceutical.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $14.0M
- Funding stage: Seed
- Last round: Seed (Aug 2024)
- Website: amlogenyx.com
- Phone: +1 415-231-3300
Industries & Categories
Biotechnology, Genetics, Therapeutics
Canonical: https://fsome.com/organization/amlogenyx-96922 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.